Table 2.

United States and Canada GBS Seroprevalences Relative to Madigan Distribution

							Prevalence by Serotype (%)
Location	Study Interval	Patient Population	Typing method	total # patients	% GBS+	# Total Iso-lates	Iaa	Ib	II	III	IV	V	VI	VII	VIII	NT	Ref
WA (Madigan)	2010	Women	PCR	1129	18.3	207	29	12	12	27	2	17	1	0	0	1	this study
Canada Alberta	1998-2000	Gravidas	OID	NA	NA	118	20	9	9	15	0	28			0	20	[15]
Canada Calgary	1998-2000	Gravidas	OID	1207	19.5	235	23	11	13	21	2	19			0.4	11	[15]
MA Boston	1999	>94% Women	ELISA	NA	NA	114	25	5	10	24	0	32	0		0.9	4	[23]
MA Boston	1962-1963	>90% Women	ELISA	NA	NA	149	46	14	11	22		0			0	7	[23]
MI	1997-2000	Adults	DB	NA	NA	338	21	12	13	13	1	22	2	0	0.3	12	[20]
MI	1999-2000	Gravidas	LCP	NA	NA	117	18	11	11	19	1	20	2			17	[19]
MIc	1999-2000	92% Adults	DB	NA	NA	306	23	12	14	11	3	30	3	0.7	2	1	[12]
MN	1974- 1975	3rd Trimester Gravidas	CP	802	5.6	45	26	13	24	24						13	[17]
MN	1993-1999	Adults	NA	NA	NA	138	21	14	16	5	0.7	35				9	[24]
OH	2001-2002	Gravidas, urine cultures	LCP	65	2.8	2318	23	4	4	32	2	6				30	[21]
OH	2003			NA	NA	349	18	9	11	17		27					[14]
PA Pittsburgh	1993-2002	non pregnant women	IP	NA	NA	2660	34	11	13	25	0.4	15	0.3	0	0.3	2	[16]
PA Pittsburgh	1998-2000	non pregnant women	DB	NA	NA	177b	31	9	15	28	0.6	14				3	[22,26]
TX	1994-1995	Gravidas	AS	546	28	153	24	9	26	24	0	12				4	[18]
WA, TX Seattle; Houston	1992-1995	Gravidas	ID	3307	26	856	26	8	18	21	0	21	0.2			1	[13]
WV	1999	Females	LA	NA	NA	84	19	13	9	15	4	15				9	[25]

a--Ic from earlier studies is grouped with Ia

b--of 270 GBS+ patients, 177 were serotyped

c--mixed population: 267 adults - Michigan, 24 neonates - Houston, TX

Madigan-Madigan Healthcare System, Tacoma, WA

LCP-Lancefield capillary precipitin

OID-Ouchterlony immunodiffusion

DBC-dotblot capsular typing

ID-immunodiffusion with rabbit antisera

IP-immunoprecipitation in agarose

LA-latex agglutination with serotype specific sera

NA-not available

AS-antisera